Siemens Healthineers AG : The underlying trend is to the upside
Entry price | Target | Stop-loss | Potential |
---|
€56.96 |
€67.2 |
€50.7 |
+17.98% |
---|
Shares in Siemens Healthineers AG show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Summary● The company presents an interesting fundamental situation from a short-term investment perspective.
● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● Over the past four months, analysts' average price target has been revised upwards significantly.
● The opinion of analysts covering the stock has improved over the past four months.
Weaknesses● The group shows a rather high level of debt in proportion to its EBITDA.
● With an enterprise value anticipated at 3.72 times the sales for the current fiscal year, the company turns out to be overvalued.
● The company appears highly valued given the size of its balance sheet.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.